000180676 001__ 180676
000180676 005__ 20240229145628.0
000180676 0247_ $$2doi$$a10.1007/s00066-022-01975-6
000180676 0247_ $$2pmid$$apmid:35833963
000180676 0247_ $$2ISSN$$a0179-7158
000180676 0247_ $$2ISSN$$a1439-099X
000180676 0247_ $$2altmetric$$aaltmetric:132518458
000180676 037__ $$aDKFZ-2022-01476
000180676 041__ $$aEnglish
000180676 082__ $$a610
000180676 1001_ $$0P:(DE-HGF)0$$aSprave, Tanja$$b0
000180676 245__ $$aCost effectiveness and health-related quality of life of chemoradiotherapy versus radiation therapy alone in elderly head and neck cancer patients.
000180676 260__ $$aHeidelberg$$bSpringer Medizin$$c2022
000180676 3367_ $$2DRIVER$$aarticle
000180676 3367_ $$2DataCite$$aOutput Types/Journal article
000180676 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674638029_13517
000180676 3367_ $$2BibTeX$$aARTICLE
000180676 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180676 3367_ $$00$$2EndNote$$aJournal Article
000180676 500__ $$a2022 Nov;198(11):1008-1015 / #LA:E055#
000180676 520__ $$aRadiotherapy (RT) constitutes a mainstay in the treatment of elderly patients with head and neck cancer (HNC), but use of simultaneous chemoradiotherapy (CRT) remains controversial. We have conducted a prospective analysis based on real-world patient data to examine the health-related quality of life (HRQoL) and cost effectiveness (CE) of CRT vs. RT in elderly HNC patients.Eligible participants ≥ 65 years treated in a large tertiary cancer center between July 2019 and February 2020 who completed the validated EQ-5D-5L questionnaire (health state index [HI] and visual analog scale [VAS]) before and after RT were included. CE referred to direct medical costs, including diagnosis-related group (DRG)-based billings for inpatients and uniform assessment standard (EBM)-based costs for outpatients. The primary endpoint was cost (euros [€]) per quality-adjusted life year (QALY). The incremental cost-effectiveness ratios (ICERs) were calculated. Costs and QALYs were not discounted for short overall survival (OS).Baseline HRQoL was 0.878 (±0.11) in the CRT group and 0.857 (±0.17) in the RT group. Upon completion of therapy, HRQoL amounted to 0.849 (±0.14) in the CRT and 0.850 (±0.13) in the RT group. The mean treatment-related cost in the CRT cohort was €22,180.17 (±8325.26) vs. €18,027.87 (±26,022.48) in the RT group. The corresponding QALYs amounted to 2.62 in the CRT and 1.91 in the RT groups. The ICER was €5848.31.This is the first analysis from the German health care system demonstrating that the addition of chemotherapy to RT for selected elderly HNC patients is cost effective and not associated with a significant HRQoL decline.
000180676 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000180676 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180676 650_7 $$2Other$$aChemoradiation
000180676 650_7 $$2Other$$aEQ‑5D
000180676 650_7 $$2Other$$aGeriatric patients
000180676 650_7 $$2Other$$aHead and neck squamous cell carcinoma
000180676 650_7 $$2Other$$aQuality-adjusted life year
000180676 7001_ $$aVerma, Vivek$$b1
000180676 7001_ $$0P:(DE-HGF)0$$aFabian, Alexander$$b2
000180676 7001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b3
000180676 7001_ $$0P:(DE-HGF)0$$aBaltas, Dimos$$b4
000180676 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b5
000180676 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils$$b6$$eLast author
000180676 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-022-01975-6$$n11$$p1008-1015$$tStrahlentherapie und Onkologie$$v198$$x0179-7158$$y2022
000180676 909CO $$ooai:inrepo02.dkfz.de:180676$$pVDB
000180676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000180676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000180676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000180676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000180676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000180676 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000180676 9141_ $$y2022
000180676 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-26$$wger
000180676 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000180676 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-26
000180676 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000180676 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2021$$d2022-11-11
000180676 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000180676 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000180676 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000180676 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000180676 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-11
000180676 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000180676 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-11
000180676 9202_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000180676 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000180676 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000180676 980__ $$ajournal
000180676 980__ $$aVDB
000180676 980__ $$aI:(DE-He78)FR01-20160331
000180676 980__ $$aI:(DE-He78)E055-20160331
000180676 980__ $$aUNRESTRICTED